March 19, 2024

Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors

Company Announces Appointment of Daniel Flynn, Ph.D. and Brian Cali, Ph.D. to Strengthen Capabilities in Support of Company’s Peptide Drug

March 5, 2024

Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners

Investment strengthens Argonaut’s leadership position in sterile fill / finish and expands the Company’s aseptic drug product manufacturing capabilities in

February 7, 2024

n6 Tec Completes Growth Financing from Telegraph Hill Partners to Support Launch of Novel iconPCR™ Platform

Pleasanton, California – February 7, 2024 – n6 Tec Inc., a next generation sequencing and molecular biology platform company, announced

February 6, 2024

n6 Tec Launches Novel iconPCR™ Platform for Individually Controlled Plate-Based Thermocycling

iconPCR enables optimal high-throughput PCR for next generation sequencing and molecular biology applications PLEASANTON, CA – February 6, 2024— n6

November 1, 2023

Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program

Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services REDWOOD CITY, Calif., Nov.

August 23, 2023

Cell Microsystems Acquires Fluxion Biosciences to Broaden Cell Analysis Product and Services Portfolio

Positions the Company as a new leader in providing solutions that bridge the gap between cellular electrophysiology and advanced analysis

March 15, 2023

Panome Bio Raises Growth Capital From Telegraph Hill Partners To Expand Next-Generation Metabolomics & Proteomics Business

ST. LOUIS, March 15, 2023 /PRNewswire/ — Panome Bio, a metabolomics and proteomics services company that provides biopharma innovators unparalleled

January 9, 2023

QIAGEN completes acquisition of Verogen, strengthening leadership in Human ID / Forensics with NGS technologies

VENLO, The Netherlands & SAN DIEGO–(BUSINESS WIRE)– QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced it has completed the acquisition of

January 5, 2023

Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech

Madison, WI USA, January 5, 2023–/BusinessWire/ — Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify

December 13, 2022

Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments

MADISON, WI, USA, December 13, 2022 — Nimble Therapeutics Inc., a leading peptide therapeutics company, today announced they have achieved

Category: News